M
METiS Therapeutics
Biotech & Life Sciences · Cambridge, United States · Founded 2017 Unicorn
Ownership
Who owns METiS Therapeutics
Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (2026). Percentages are indicative.
Some investors are hidden on this public profile. See the full cap table on Dealroom →
Global footprint
Where METiS Therapeutics has talent and traffic
across markets
Talent graph
The shape of METiS Therapeutics's talent
Dealroom maps METiS Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.
Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.
Market sentiment
What the market is saying about METiS Therapeutics
An AI-synthesized read of the highest-engagement posts about METiS Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See METiS Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.